Press Releases July 28, 2026 05:40 PM

Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting

Seer Stockholders Re-elect Entire Board of Directors at 2026 Annual Meeting, Reinforcing Confidence in Strategic Direction

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
SEER

Seer, Inc. announced that its stockholders voted to re-elect all seven nominees to its Board of Directors at the 2026 Annual Meeting. The company expressed confidence in its board's expertise and reiterated its commitment to advancing its proteomics technology, scaling commercialization, and disciplined execution of its strategy to drive long-term value.

Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting
SEER
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • All seven director nominees were re-elected, reflecting stockholder confidence in the current board and company leadership.
  • Seer is focused on expanding utilization of its proteomics platform, increasing participation in population-scale studies, and advancing its innovation pipeline.
  • The company emphasizes disciplined cost management while scaling commercialization efforts.
  • The proteomics sector and biotechnology market are impacted by Seer's ongoing developments and governance stability.

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer”) today announced that, based on the preliminary voting results from Seer’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), Seer stockholders have voted to re-elect all seven of Seer’s director nominees – Omid Farokhzad, M.D.; Meeta Gulyani; Robert Langer, Sc.D.; Terrance McGuire; Dipchand (Deep) Nishar; Isaac Ro; and Nicolas Roelofs, Ph.D. – to Seer’s Board of Directors (the “Board”).

Seer issued the following statement:

We thank our stockholders for their support and engagement over the last several months. This outcome reflects confidence in Seer’s highly qualified, purpose-built Board and our directors’ commitment to advancing the best interests of all stockholders. We remain focused on disciplined execution of our strategy that includes expanding utilization of our growing installed base, securing additional population-scale cohort and biobank studies, advancing our innovation pipeline and scaling platform commercialization with continued cost discipline. The business is building momentum, and we remain confident in Seer’s ability to drive value creation over the long-term.

The voting results announced today are considered preliminary until final results are tabulated and certified by the independent inspector of elections. Seer expects to report the final certified voting results for all proposals on a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.

About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at [email protected].

Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this communication. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s strategy, execution and business momentum. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
[email protected]

Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449

Investor Contact:
Marissa Bych
[email protected]


Risks

  • Forward-looking statements cite uncertainties related to execution of strategy and business momentum that may impact actual results.
  • Potential risks inherent in scaling commercialization and securing additional large-scale cohort studies.
  • Market and regulatory risks impacting the biotechnology and proteomics sectors could affect Seer's performance.

More from Press Releases

Broadwind Announces Second Quarter 2026 Results Conference Call and Webcast Date Jul 28, 2026 Westport to Issue Q2 2026 Financial Results on August 11, 2026 Jul 28, 2026 NOV Reports Second Quarter 2026 Earnings Jul 28, 2026 Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026 Jul 28, 2026 Kentucky First Federal Bancorp Board of Directors Announces Declaration of $0.05 Quarterly Dividend Jul 28, 2026